Ficlatuzumab 是一种靶向人肝细胞生长因子 (HGF) 的单克隆抗体 (McAb)。Ficlatuzumab 能够阻断 HGF/c-Met 信号通路的激活，抑制 c-Met 受体介导的癌细胞增殖、迁移和侵袭。

Ficlatuzumab is a monoclonal antibody (McAb) targeting human hepatocyte growth factor (HGF). Ficlatuzumab blocks the activation of the HGF/c-Met signaling pathway, and inhibits c-Met receptor-mediated cancer cell proliferation, migration, and invasion.

Liquid

HGF/c-Met

Ficlatuzumab (20 μg/mL; 24 h) effectively decreases tumor-associated fibroblast (TAF)-conditioned media-facilitated HNSCC migration and invasion.
Ficlatuzumab (20 μg/mL; 24 h) effectively mitigates TAF-facilitated epithelial-tomesenchymal transition (EMT), Vimentin expression in HNSCC cells.
Ficlatuzumab (20 μg/mL; 72 h) reduces proliferation induced by TAF-secreted hepatocyte growth factor (HGF) in HNSCC cells.
Ficlatuzumab (20 μg/mL; 16 h) reduces the phosphorylation of c-Met and p44/42 MAPK in HNSCC cells compared with cells treated with recombinant HGF alone.
has not independently confirmed the accuracy of these methods. They are for reference only.

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

[1]. Kumar D, et al. Mitigation of Tumor-Associated Fibroblast-Facilitated Head and Neck Cancer Progression With Anti-Hepatocyte Growth Factor Antibody Ficlatuzumab. JAMA Otolaryngol Head Neck Surg. 2015 Dec;141(12):1133-9.